Magnolia Medical Technologies makes a product that aims to reduce the rate of false positive diagnoses of sepsis.
Seattle-based Magnolia Medical Technologies has raised $13.8 million to continue developing a product that aims to provide accurate blood tests.
Magnolia makes the SteriPath blood-collection system, which is meant to decrease the number of false positives for sepsis, a complication of a bloodstream infection that is often treated with antibiotics and can be life-threatening.
Such false positives can mean that patients are given procedures and treatments they don’t need, exposing them to more risk, Magnolia said in a news release announcing the funding. More than 1 million people in the U.S. are misdiagnosed with sepsis each year, the company said.
Menlo Park, Calif.-based HealthQuest Capital led the funding round and announced managing partner Garheng Kong would join Magnolia’s board.
Most Read Stories
- Cheating hubby needs to reset attitude toward ‘affair baby’ | Dear Carolyn
- Washington state will resist federal crackdown on legal weed, AG Ferguson says
- Seattle home too toxic to enter sparked a bidding frenzy — now we know why VIEW
- T-Mobile one-ups Verizon’s new unlimited data plan; 4Q results top forecasts
- Swedish CEO resigns in wake of Seattle Times investigation
SteriPath is commercially available, and the company will use the investment to expand the product into hospitals.